Providing the right tools at the right time

DIALUNOX supports US diagnostics company QUIDEL in fighting against the COVID crisis providing the suitable instrument platform for molecular analysis of SARS-CoV-2 infections

On Dec 23rd, Quidel Corporation announced FDA emergency use authorization of its SARS-CoV-2 assay running on the Solana platform, manufactured by DIALUNOX GmbH. The Solana SARS-CoV-2 Assay is an isothermal Reverse Transcriptase - Helicase-Dependent Amplification (RT-HDA) assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal (NP) and nasal (NS) swab specimens from individuals suspected of COVID-19 by their healthcare provider.
The availability of this test on the Solana platform will allow users to get results of up to 11 patient samples in less than 30 minutes. This will be a tremendous step forward in ramping up patient screening also in decentralized settings having limited space available since the Solana system has a small footprint of only 23 x 20 cm (9 x 8 in).
DIALUNOX is a German provider of small and portable measurement devices utilizing highly sensitive optics modules for fluorescence detection. The company has already provided more than 2000 Solana units to its partner Quidel, ramping up now capacity to fulfill expected increased demands.
Michael Doumanas, the Managing Director of DIALUNOX underlines: “This product fits perfectly to our vision to enable faster and better decisions at the point where it's needed most”.
The US healthcare system will now have an additional powerful tool available together with the SARS-CoV-2 Assay. This will allow to narrow down the pandemic and locate new hotspots at a much earlier stage.

DIALUNOX GmbH
Bodenseeallee 20
78333 Stockach
Germany

Olga Nuebel
Senior Specialist Marketing & Sales
olga.nuebel@dialunox.com

DIALUNOX brings light to the darkness. The company operates as a strategic engineering partner for the development of complex measuring devices and as a manufacturer of compact rapid test readers. DIALONUX delivers the precise illumination and detection of fluorescence or reflective samples needed across a wide range of measurement parameters.
The company's approximately 70 employees develop, test and manufacture the measuring instruments directly at our headquarters in Stockach on Lake Constance. The one-site location of consulting, development and production departments guarantees short cycle times from idea to finished product.
DIALUNOX develops its products according to regulatory guidelines for in-vitro diagnostics and enables customers to obtain approval for their products quickly and easily.
Customers interact predominately in the fields of point of care diagnostics, food analysis or environmental analysis with need for customized measuring instruments for their tests. DIALUNOX - Light to Insight.

This release was published on openPR.